中国临床医学2011，Vol.18Issue(5)：634-635,2.
非小细胞肺癌骨转移患者用表皮生长因子受体酪氨酸激酶抑制剂治疗的预后因素分析
Analysis of Prognostic Factors of Non-Small Cell Lung Carcinoma Patients with Bone Metastases Treated with Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor
田军 1刘辉 2姬巍 1张萍海 1曾昭冲 1洪群英 1白春学1
作者信息
- 1. 复旦大学附属中山医院放疗科,上海200032
- 2. 同济大学附属上海肺科医院放疗科,上海200433
- 折叠
摘要
Abstract
Objective:To analyze the prognostic factors of non-small cell lung carcinoma patients with bone metastases treated with epidermal growth factor receptor tyrosine kinase inhibitorC EGFR-TKI). Methods: The clinical data of 132 non-small cell lung carcinoma patients with bone metastases treated with EGFR-TKI, admitted in Zhongshan Hospital of Fudan University and Shanghai Pulmonary Hospital of Tongji University during January 2009 to December 2010, were retrospectively researched. Kaplan-Meier analysis was used to estimate the 1-year and 2-year survival rates of patients. Log-rank test was used to screen the survival influencing factors and Cox regression was further used to confirm the independent factors. Results: The median survival of the 132 patients was 15. 9 months. The 1-year and 2-year survival rates were 63. 9% and 41. 5%, respectively. Univariate analysis showed that female, nonsmoker, normal serum albumin lever were associated with the good prognosis of patients (P<0.05), while multivariate analysis only revealed that serum albumin level was the independent factor of prognosis. Conclusions: The treatment with EGFR-TKI tends to prolong the median survival time of non-small ceil lung carcinoma patients with bone metastases who are female and nonsmokers. Low serum albumin level is an unfavorable prognostic factor.关键词
非小细胞肺癌/骨转移/EGFR-TKIKey words
Non-small cell lung carcinoma/Bone metastasis/EGFR-TKI分类
医药卫生引用本文复制引用
田军,刘辉,姬巍,张萍海,曾昭冲,洪群英,白春学..非小细胞肺癌骨转移患者用表皮生长因子受体酪氨酸激酶抑制剂治疗的预后因素分析[J].中国临床医学,2011,18(5):634-635,2.
